PAVmed Reports Going Concern, Secures $30M Financing & Warrants, Regains Nasdaq Compliance
PAVM sits 45% above its 52-week low of $6.
Summary
PAVmed's annual report reveals a going concern warning but details successful, albeit dilutive, capital raises totaling over $30 million in gross proceeds, alongside key operational and regulatory progress for its subsidiaries, and regaining Nasdaq compliance.
Key Events · Financing and Capital Events · PAVM
-
Going Concern Warning Issued
The company's financial statements include an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern, citing recurring losses and negative cash flows.
-
Secured $30M Series D Preferred Stock Offering
PAVmed completed a $30 million Series D Preferred Stock offering, including warrants, which yielded approximately $7.6 million in net proceeds after redeeming Series C Preferred Stock and refinancing existing debt. The Series D Preferred Stock was converted into 4,615,393 common shares on March 27, 2026, and warrants for an additional 4,615,393 common shares remain outstanding, potentially bringing in another $30 million upon exercise.
-
Regained Nasdaq Compliance
Following a 1-for-30 reverse stock split effective January 2, 2026, and a reduction in authorized common shares from 250 million to 25 million, PAVmed regained compliance with Nasdaq's $1 minimum bid price requirement on January 21, 2026.
-
Lucid Diagnostics Achieves Key Milestones
Lucid Diagnostics was awarded a contract by the U.S. Department of Veterans Affairs for its EsoGuard test and received positive updates to NCCN Clinical Practice Guidelines and Highmark Blue Cross Blue Shield reimbursement policy.
Analysis · PAVM · Industrial Applications And Services
PAVmed's annual report for 2025 highlights substantial doubt about its ability to continue as a going concern, a critical financial warning. Despite this, the company successfully executed significant financing activities, including a $30 million Series D Preferred Stock offering and warrants, which provided $7.6 million in net proceeds after debt and preferred stock redemptions. Shareholders approved the conversion of the Series D Preferred Stock into common stock and an increase of 1.5 million shares to the equity incentive plan. The company also regained compliance with Nasdaq's minimum bid price requirement following a 1-for-30 reverse stock split. Operationally, Lucid Diagnostics secured a VA contract and positive NCCN guideline updates, while Veris Health launched a strategic partnership. These capital raises and operational advancements are crucial for extending the company's runway amidst its financial challenges.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 36.1% of the 1758 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.05%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PAVM was trading at $8.67 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13M. The 52-week trading range was $6.00 to $28.44. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.